| 摘要 |
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkenyl, aryl (C<SUB>0</SUB>-C<SUB>4</SUB>)alkyl, aryloxy(C<SUB>0</SUB>-C<SUB>4</SUB>)alkyl, arylthio(C<SUB>0</SUB>-C<SUB>4</SUB>)alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C<SUB>1</SUB>-C<SUB>5</SUB>alkyl, C<SUB>1</SUB>-C<SUB>5</SUB>alkenyl, and arylC<SUB>0</SUB>-C<SUB>3</SUB>alkyl. (c) T<SUB>1 </SUB>is selected from the group consisting of C and N, (d) W is selected from the group consisting of CH<SUB>2</SUB>, C(O)N(R21), N(R21), N(R21)CH<SUB>2</SUB>, O, OCH<SUB>2</SUB>, S, and SO<SUB>2</SUB>; and (e) X is selected from the group consisting of C, CH<SUB>2</SUB>C, and CCH<SUB>2</SUB>
|
